AU2007213716C1 - Antigenic GM-CSF peptides and antibodies to GM-CSF - Google Patents

Antigenic GM-CSF peptides and antibodies to GM-CSF Download PDF

Info

Publication number
AU2007213716C1
AU2007213716C1 AU2007213716A AU2007213716A AU2007213716C1 AU 2007213716 C1 AU2007213716 C1 AU 2007213716C1 AU 2007213716 A AU2007213716 A AU 2007213716A AU 2007213716 A AU2007213716 A AU 2007213716A AU 2007213716 C1 AU2007213716 C1 AU 2007213716C1
Authority
AU
Australia
Prior art keywords
seq
csf
cells
antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007213716A
Other languages
English (en)
Other versions
AU2007213716B2 (en
AU2007213716A1 (en
Inventor
Qimin Chao
Wolfgang Ebel
Luigi Grasso
Jian Li
Nicholas E. Nicolaides
Eric Routhier
Philip M. Sass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007213716(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of AU2007213716A1 publication Critical patent/AU2007213716A1/en
Application granted granted Critical
Publication of AU2007213716B2 publication Critical patent/AU2007213716B2/en
Priority to AU2013201228A priority Critical patent/AU2013201228B2/en
Publication of AU2007213716C1 publication Critical patent/AU2007213716C1/en
Assigned to EISAI, INC. reassignment EISAI, INC. Request for Assignment Assignors: MORPHOTEK, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
AU2007213716A 2006-02-08 2007-02-08 Antigenic GM-CSF peptides and antibodies to GM-CSF Ceased AU2007213716C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013201228A AU2013201228B2 (en) 2006-02-08 2013-03-04 Antigenic gm-csf peptides and antibodies to gm-csf

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77125106P 2006-02-08 2006-02-08
US60/771,251 2006-02-08
US77450006P 2006-02-17 2006-02-17
US60/774,500 2006-02-17
PCT/US2007/061874 WO2007092939A2 (en) 2006-02-08 2007-02-08 Antigenic gm-csf peptides and antibodies to gm-csf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013201228A Division AU2013201228B2 (en) 2006-02-08 2013-03-04 Antigenic gm-csf peptides and antibodies to gm-csf

Publications (3)

Publication Number Publication Date
AU2007213716A1 AU2007213716A1 (en) 2007-08-16
AU2007213716B2 AU2007213716B2 (en) 2012-12-06
AU2007213716C1 true AU2007213716C1 (en) 2015-05-07

Family

ID=38345964

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007213716A Ceased AU2007213716C1 (en) 2006-02-08 2007-02-08 Antigenic GM-CSF peptides and antibodies to GM-CSF

Country Status (18)

Country Link
US (5) US7741450B2 (https=)
EP (2) EP3181585A3 (https=)
JP (1) JP5210889B2 (https=)
KR (2) KR101395515B1 (https=)
CN (1) CN101501070B (https=)
AU (1) AU2007213716C1 (https=)
CA (2) CA2961031C (https=)
CY (1) CY1118709T1 (https=)
DK (1) DK1981909T3 (https=)
ES (1) ES2609088T3 (https=)
HR (1) HRP20170024T1 (https=)
HU (1) HUE032584T2 (https=)
IL (2) IL193011A (https=)
LT (1) LT1981909T (https=)
PL (1) PL1981909T3 (https=)
PT (1) PT1981909T (https=)
RS (1) RS55526B1 (https=)
WO (1) WO2007092939A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608281B8 (pt) 2005-04-18 2021-05-25 Amgen Res Munich Gmbh anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US7741450B2 (en) 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
JP2009533072A (ja) * 2006-04-17 2009-09-17 モルフォテック、インク． 細胞によるタンパク質および抗体収量を改善するために適用される全ゲノム進化技術
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
EP2101780B1 (en) * 2006-11-21 2013-10-09 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
JP5607530B2 (ja) 2007-09-04 2014-10-15 コンピュゲン エルティーディー． ポリペプチド並びにポリヌクレオチド、並びに薬剤および生物製剤生産のための薬剤標的としてのその利用
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009062238A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
JP5476310B2 (ja) * 2008-02-14 2014-04-23 株式会社イーベック ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
JP2012105657A (ja) * 2008-02-14 2012-06-07 Evec Inc ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
EP2282757B1 (en) * 2008-04-07 2013-05-22 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
WO2009134805A2 (en) * 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
CA2717987C (en) * 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
CA2747206C (en) * 2008-12-22 2018-04-24 The University Of Melbourne Pain treatment
CN102271705A (zh) * 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
US20130046015A1 (en) * 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2013026059A1 (en) 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
CN104212760B (zh) * 2013-05-29 2017-08-08 中国科学院上海生命科学研究院 肌肉干细胞体外培养方法及其应用
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
ES2626491B1 (es) 2015-12-03 2018-06-25 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpos monoclonales frente a bambi y uso para tratamiento de enfermedades inflamatorias
SG11201901789WA (en) 2016-09-19 2019-03-28 I Mab Anti-gm-csf antibodies and uses thereof
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
EP3634487A4 (en) 2017-06-09 2021-03-24 The Regents Of The University Of Colorado, A Body Corporate, A Colorado Non-Profit GM-CSF MIMETICS AND PROCESSES FOR THE PRODUCTION AND USE OF THEM
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
AU2018345751A1 (en) 2017-10-02 2020-05-07 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
JP7603580B2 (ja) 2018-10-15 2024-12-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用
WO2020092850A1 (en) * 2018-10-31 2020-05-07 Humanigen, Inc. Materials and methods for treating cancer
WO2021207667A1 (en) * 2020-04-10 2021-10-14 Kinevant Sciences Gmbh Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
CN117384856B (zh) * 2023-09-04 2024-04-16 广州医科大学 一种永生化copd人支气管上皮细胞株及其构建方法和应用
CN120399067B (zh) * 2025-07-02 2025-09-30 武汉伊莱瑞特生物科技股份有限公司 一种与人gm-csf特异性结合的单克隆抗体及其检测试剂盒和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499161A2 (en) * 1991-02-11 1992-08-19 Bristol-Myers Squibb Company GM-CSF inhibiting antibodies
WO2004046330A2 (en) * 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
EP1593690A1 (en) * 2004-05-05 2005-11-09 Micromet AG Preparation of ScFv antibody fragments

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US6013619A (en) 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
EP0482086A1 (en) 1989-07-14 1992-04-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
BR9205151A (pt) 1992-08-17 1994-03-01 Praxair Technology Inc Dissolucao aumentada de gas
AU2322097A (en) 1996-03-27 1997-10-17 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6120795A (en) 1996-03-27 2000-09-19 Ortho Pharmaceutical Corp. Manufacture of liposomes and lipid-protein complexes by ethanolic injection and thin film evaporation
US6013764A (en) 1996-07-17 2000-01-11 Ortho Pharmaceutical Corp. Liquid phase peptide synthesis of KL-4 pulmonary surfactant
EP0959136A1 (en) 1998-05-20 1999-11-24 Introgene B.V. Targeted delivery through a cationic amino acid transporter
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
CA2430013C (en) * 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
KR20030082962A (ko) 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ)
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US7396915B2 (en) 2003-02-28 2008-07-08 Mitsubishi Pharma Corporation Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
JP2005040126A (ja) * 2003-02-28 2005-02-17 Mitsubishi Pharma Corp モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
WO2005014652A1 (en) 2003-08-05 2005-02-17 Morphotek, Inc. A variant cell surface molecule associated with cancer
JP2005176792A (ja) 2003-12-24 2005-07-07 Atex Co Ltd 乗用草刈機
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
BRPI0608281B8 (pt) * 2005-04-18 2021-05-25 Amgen Res Munich Gmbh anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende
RU2447085C2 (ru) * 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US7741450B2 (en) 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499161A2 (en) * 1991-02-11 1992-08-19 Bristol-Myers Squibb Company GM-CSF inhibiting antibodies
WO2004046330A2 (en) * 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
EP1593690A1 (en) * 2004-05-05 2005-11-09 Micromet AG Preparation of ScFv antibody fragments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kanakura et al (1991) Blood, March 77(5):1033-1043 *

Also Published As

Publication number Publication date
PT1981909T (pt) 2017-01-18
CA2641169C (en) 2017-05-02
RS55526B1 (sr) 2017-05-31
EP1981909A2 (en) 2008-10-22
US20130058945A1 (en) 2013-03-07
WO2007092939A8 (en) 2009-07-23
CN101501070B (zh) 2013-12-25
EP1981909B1 (en) 2016-10-12
KR20130124420A (ko) 2013-11-13
IL193011A (en) 2015-06-30
IL235050A (en) 2017-03-30
US7741450B2 (en) 2010-06-22
LT1981909T (lt) 2017-01-10
EP3181585A2 (en) 2017-06-21
US8318168B2 (en) 2012-11-27
JP5210889B2 (ja) 2013-06-12
HUE032584T2 (en) 2017-09-28
ES2609088T3 (es) 2017-04-18
KR20080099314A (ko) 2008-11-12
IL193011A0 (en) 2009-02-11
JP2009526082A (ja) 2009-07-16
US9422367B2 (en) 2016-08-23
US20100272730A1 (en) 2010-10-28
PL1981909T3 (pl) 2017-08-31
DK1981909T3 (en) 2017-01-23
CN101501070A (zh) 2009-08-05
US10023632B2 (en) 2018-07-17
US20080292641A1 (en) 2008-11-27
US8623364B2 (en) 2014-01-07
WO2007092939A2 (en) 2007-08-16
KR101395515B1 (ko) 2014-05-14
CA2961031A1 (en) 2007-08-16
CY1118709T1 (el) 2017-07-12
CA2961031C (en) 2020-02-25
HRP20170024T1 (hr) 2017-03-10
EP3181585A3 (en) 2017-08-30
KR101486183B1 (ko) 2015-01-28
US20140086928A1 (en) 2014-03-27
CA2641169A1 (en) 2007-08-16
US20160333089A1 (en) 2016-11-17
AU2007213716B2 (en) 2012-12-06
WO2007092939A3 (en) 2008-03-27
AU2007213716A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
AU2007213716C1 (en) Antigenic GM-CSF peptides and antibodies to GM-CSF
CN101321783B (zh) 人抗-b7rp1中和抗体
DK2892562T3 (en) ANTI-MCAM ANTIBODIES AND RELATED METHODS OF APPLICATION
HUE025778T2 (en) Preparations and methods for the use of therapeutic antibodies
AU2013201228B2 (en) Antigenic gm-csf peptides and antibodies to gm-csf
AU2017200408B2 (en) Human anti-B7RP1 neutralizing antibodies
AU2011265342B2 (en) Human anti-B7RP1 neutralizing antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JAN 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JAN 2015

PC Assignment registered

Owner name: EISAI, INC.

Free format text: FORMER OWNER(S): MORPHOTEK, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired